PTC Therapeutics, Inc. Inventory Write-down
PTC Therapeutics, Inc. (PTCT) reported Inventory Write-down of $900.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-07-30
- PTC Therapeutics, Inc. inventory write-down for the quarter ending 2026-06-30 was $900.00K, a 12.50% increase year-over-year.
- PTC Therapeutics, Inc. inventory write-down for the quarter ending 2026-03-31 was $1.80M, a 48.57% decline year-over-year.
- PTC Therapeutics, Inc. inventory write-down for the quarter ending 2025-12-31 was $400.00K, a 96.26% decline year-over-year.
- PTC Therapeutics, Inc. inventory write-down for the quarter ending 2025-09-30 was $500.00K.
- PTC Therapeutics, Inc. inventory write-down for fiscal 2025 was $5.20M, a 60.61% decline from fiscal 2024.
- PTC Therapeutics, Inc. inventory write-down for fiscal 2024 was $13.20M, a 5.60% increase from fiscal 2023.
- PTC Therapeutics, Inc. inventory write-down for fiscal 2023 was $12.50M, a 635.29% increase from fiscal 2022.
- PTC Therapeutics, Inc. inventory write-down for fiscal 2022 was $1.70M, a 22.73% decline from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $900.00K 10-Q · filed 2026-07-30 | $2.70M 10-Q · filed 2026-07-30 | $3.10M derived: sum of 3 quarters · filed 2026-07-30 | $3.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.80M 10-Q · filed 2026-05-07 | $2.20M derived: sum of 2 quarters · filed 2026-05-07 | $2.70M derived: sum of 3 quarters · filed 2026-05-07 | $3.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $900.00K derived: sum of 2 quarters · filed 2026-02-19 | $1.70M derived: sum of 3 quarters · filed 2026-07-30 | $5.20M 10-K · filed 2026-02-19 |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-04 | $1.30M derived: sum of 2 quarters · filed 2026-07-30 | $4.80M 10-Q · filed 2025-11-04 | $15.50M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $800.00K 10-Q · filed 2026-07-30 | $4.30M 10-Q · filed 2026-07-30 | $15.00M derived: sum of 3 quarters · filed 2026-07-30 | $14.90M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $3.50M 10-Q · filed 2026-05-07 | $14.20M derived: sum of 2 quarters · filed 2026-05-07 | $14.10M derived: sum of 3 quarters · filed 2026-05-07 | $13.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $10.60M derived: sum of 2 quarters · filed 2026-02-19 | $9.50M derived: sum of 3 quarters · filed 2026-02-19 | $13.20M 10-K · filed 2026-02-19 |
| 2024-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.20M derived: sum of 2 quarters · filed 2025-11-04 | $2.50M 10-Q · filed 2025-11-04 | $14.60M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.60M 10-Q · filed 2025-08-07 | $14.70M derived: sum of 3 quarters · filed 2025-08-07 | $14.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $3.70M 10-Q · filed 2025-05-06 | $15.80M derived: sum of 2 quarters · filed 2025-05-06 | $15.80M derived: sum of 3 quarters · filed 2025-05-06 | $16.10M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $12.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $12.10M derived: sum of 2 quarters · filed 2025-02-27 | $12.40M derived: sum of 3 quarters · filed 2025-02-27 | $12.50M 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $300.00K derived: sum of 2 quarters · filed 2024-11-07 | $400.00K 10-Q · filed 2024-11-07 | $900.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-08 | $400.00K 10-Q · filed 2024-08-08 | $900.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.20M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $100.00K 10-Q · filed 2024-04-25 | $600.00K derived: sum of 2 quarters · filed 2024-04-25 | $900.00K derived: sum of 3 quarters · filed 2024-04-25 | $1.20M derived: sum of 4 quarters · filed 2024-04-25 |
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $800.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.10M derived: sum of 3 quarters · filed 2024-02-29 | $1.70M 10-K · filed 2024-02-29 |
| 2022-09-30 | $300.00K 10-Q · filed 2023-10-26 | $600.00K derived: sum of 2 quarters · filed 2023-10-26 | $1.20M 10-Q · filed 2023-10-26 | $1.20M derived: sum of 4 quarters · filed 2023-10-26 |
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-03 | $900.00K 10-Q · filed 2023-08-03 | $900.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.40M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $600.00K 10-Q · filed 2023-04-27 | $600.00K derived: sum of 2 quarters · filed 2023-04-27 | $1.10M derived: sum of 3 quarters · filed 2023-04-27 | $1.40M derived: sum of 4 quarters · filed 2023-04-27 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $500.00K derived: sum of 2 quarters · filed 2023-02-21 | $800.00K derived: sum of 3 quarters · filed 2023-02-21 | $2.20M 10-K · filed 2023-02-21 |
| 2021-09-30 | $500.00K 10-Q · filed 2022-10-27 | $800.00K derived: sum of 2 quarters · filed 2022-10-27 | $2.20M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-04 | $1.70M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $1.40M 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $500.00K 10-K · filed 2022-02-22 | |||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $200.00K 10-Q · filed 2021-07-29 | $600.00K derived: sum of 3 quarters · filed 2021-07-29 | $600.00K derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-04 | $600.00K derived: sum of 2 quarters · filed 2021-05-04 | $600.00K derived: sum of 3 quarters · filed 2021-05-04 | $600.00K derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $400.00K derived: sum of 2 quarters · filed 2021-02-25 | $400.00K derived: sum of 3 quarters · filed 2021-02-25 | $400.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $0.00 10-Q · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-04-30 | |||
| 2018-12-31 | $1.80M 10-K · filed 2020-03-02 | |||
| 2018-09-30 | $1.60M 10-Q · filed 2019-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |